STOCK TITAN

Kala Bio Inc. - KALA STOCK NEWS

Welcome to our dedicated news page for Kala Bio (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on Kala Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kala Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kala Bio's position in the market.

Rhea-AI Summary
KALA BIO, Inc. announced that its CEO will present at the TD Cowen 44th Annual Healthcare Conference in March 2024. The company focuses on developing therapies for eye diseases. Investors can access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
conferences
-
Rhea-AI Summary
KALA BIO, Inc. (KALA) to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference. A pre-recorded fireside chat will be available on February 13, 2024. Management will also be available for one-on-one meetings. Webcast and archived recording accessible on KALA website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conferences
-
Rhea-AI Summary
KALA BIO, Inc. granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options allow purchase of up to 3,125 shares of its common stock. The exercise price is $7.85 per share, with a ten-year term and vesting over four years. The grant was approved by the Compensation Committee and made as a material inducement to the employee entering into employment with KALA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
KALA BIO, Inc. (NASDAQ:KALA) reported Q3 2023 financial results and corporate update. Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024. As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM award, expected to fund operations into 2Q 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
earnings
-
Rhea-AI Summary
KALA BIO grants stock options to new employee as inducement award
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
Rhea-AI Summary
KALA BIO to present at H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.58%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
earnings
-
Rhea-AI Summary
KALA BIO, Inc. (Nasdaq:KALA) to participate in multiple investor conferences in August 2023, presenting at Wedbush PacGrow Healthcare Conference, H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference, and Sidoti Micro Cap Conference. Webcast and archived recordings available on Kala website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
conferences
-
Rhea-AI Summary
Kala Pharmaceuticals, Inc. (Nasdaq:KALA) will change its name to KALA BIO, Inc. effective August 2, 2023, to better reflect the company’s focus on advancing biologics for the treatment of ophthalmic conditions. KALA BIO is progressing an innovative pipeline built on its proprietary mesenchymal stem cell secretome (MSC-S) platform, which is designed to provide a cell-free, regenerative approach to disease management, with the potential to treat multiple diseases of the front and back of the eye.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
Kala Bio Inc.

Nasdaq:KALA

KALA Rankings

KALA Stock Data

21.14M
2.05M
18.77%
23.78%
0.37%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Watertown

About KALA

kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.